MONTREAL, QUEBEC--(Marketwire - September 16, 2008) - Ambrilia Biopharma Inc. (TSX: AMB) today announced that it has succeeded in manufacturing a final 1-month formulation of goserelin intended for the treatment of prostate cancer and several gynecological indications. The Company has already developed a proprietary, novel 3-month formulation of goserelin for which a Phase I/II clinical program in prostate cancer patients was initiated in July 2008.
